ekonominyheter

TranslateRSSMobil
Sarepta Therapeutics Sees Setback in Eteplirsen Drug Application

Sarepta Therapeutics Sees Setback in Eteplirsen Drug Application

Wall Street Journal 27/10 09:53

Sarepta Therapeutics Inc. said the U.S. Food and Drug Administration is requiring additional data for the new drug application for its Duchenne muscular dystrophy treatment eteplirsen.

Till artikeln

Ekonomi Nyheter .se - Innehåll

 

 

 

 

DMCA.com Protection Status